Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

6 activities * adherence

12th World AIDS Conference

-Keyword

Abstract

-Keyword

Abstract

ess over 6 years on the
-seropositive persons/ Activity
therapy naive patients/
with protease inhibitors/
uced pro-inflammatory activity
ted viral transcriptional
ics, safety and anti-HIV
ve subjects/Safety and
hildren/Antiretroviral
-1 protease/Anti-HIV-1
suggests residual viral
m/Synergistic anti-HIV
s (PIs)/In vitro antiviral
able clinical anti-HIV-1
DS is low/Early sexual
d patients/Telomerase
Serum HIV neutralizing
n CD45 phosphatase
potent HIV-suppressing
Study 002/Anti-tumour
ma tumour/Anti-tumour
sess the antiretroviral
pare the antiretroviral
bility and antiretroviral
cs, tolerability, anti-viral
correlation with antiviral
ase by the macrophage
)/HIV-AIDS prevention
se and high-risk sexual
A review of six years of
on of the HIV-inhibitory
HIV specific neutralizing
ction and levels of CTL
xic T lymphocyte (CTL) i
HIV function: RANTES, on HIV-1 specific CTL
c cytotoxic T-cell (CTL)
ytolytic T lymphocyte
cytosis and germicidal i
men/Testosterone, HIV
ompatible with enzyme
ne mediated HIV killing i
odel systems/Anti-viral
n (PHE) outreach/Daily f
ine (D-D4FC)/Anti-HIV
CR4 receptor/Anti-HIV
ns and AZT/Anti-HIV-1 <
eparation and anti-HIV
odeficiency virus type 1
odeficiency virus (HIV)
a reverse transcriptase /
r of HIV disease/CD45 i
asing thymidine kinase
cokinetics and antiviral i
e basis of their antiviral /
parameters of hospital
ces/Women's HIV risk
emy in Rosario/Sexual
ral treatment, 1. In vitro /
d impact of early sexual
nfected cells/Apoptotic c
in Dakar/Experimental c
e/Anticytomegaloviral
fect of natural killer cell i
tion "Krilija"/Anti-AIDS (
fected patients/Lack of
ancial support on AIDS f

of NGO worked with HIV/AIDS in 60851
of soft gelatin capsule formulation 12145
of abacavir (1592, ABC) combine 12210
of TaxotereTM (docetaxel) as thera 60934
/Generation of recombinant analo 11101
and the level of seminal chemokin 279*/11151
/Oral PMPA pro-drug: Relationshi 12211
of abacavir (1592, ABC) with 3TC/ 127*/12230
and safety of abacavir (1592, ABC 128*/12255

of and HIV-1 resistance profiles ag
/Persistent CD8+ T lymphocyte ac
of ritonavir and other protease inhi
and pharmacokinetic (PK) profiles
(72 weeks) and tolerability for efavi
is common among teenagers in th
impairment in hematopoietic prog
and IgA in exposed seronegative (
/The effect of HIV-1 infection on C
in acutely infected-reservoir cells/
of oral 9-cis-retinoic acid in AIDS r
of interleukin-4 toxin in nude mice i
and safety of efavirenz (EFV, SUS
and tolerability of efavirenz (EFV)
of efavirenz (EFV, SustivaTM DMP
and preliminary viral resistance/C
'Pharmacokinetic interaction betw
immunomodulator WF10 (A phase
among intravenous opioids users i
among STD clinic patients/Cocain
of a reference center in Rome/HIV
of seven human mucosal fluids/Ev
(NA) of HIV infected patients recei
are in equilibrium with viral burden
n HIV-1-infected Ugandan adults/
via CCR3 is required for specific T'Effect of the Thl and Th2 stimulat
against HIV-1 proteins is not assoc
using frozen PBMC and correlatio
in originating neutrophils and mon
and nutritional status in HIV-infect
Combination of the multidrug resi
nduced by Echinacea angustifolia
of microbicides in model systems/
orm as monitory tool for peer healt
biochemistry, and pharmacokineti
of AMD3465, a novel antagonist of
of combinations and covalent conj
of enantiomeric oxaselenolane nu
Structure/function relationship of t
of NARL-1, an polycassine extrac
Rapid phenotypic detection of HI
n T cells: A new surrogate marker
versus reduction of thymidine mon
n phase 1/11 trials/Relationships b
Case reports of potential combina
confirms effectiveness of new ther
as a route to greater security: The
and knowledge on AIDS: Investiga
Multiple herbal therapy: A new ap
among adolescents in relation to S
)f nitric oxide in HIV-1 -infected cell
)f reconversion among prostitutes
and toxicity studies of (-)-2-(S)-di
n AIDS patients/Interleukin (IL-2
of the St. Petersburg Gay and Les
of the protease inhibitors on the H
or NGOs in Thailand in 1995/Fina

12270
12293
12315
12339
12359
14109
21118
21124
21151
21185
22276
22279
22334
22336
22340
22352
22404
22417
407*/23220
23414
570*/23534
31106
31108
598*/31130
31139
31148
31153
31155
31156
31187
32163
32300
32309
33149
33591
557*/41174
41183
41188
41200
41206
41207
41209
42183
42264
42266
42388
42437
60060
60096
60205
60225
60255
60265
60291
60325
60595
60598
60600
33153
24270
60211
60453
12192
22228
24239
60882
11222
11224
11225
12189
12190

therapy in patients with /primary HIV infection/Double nude
ina/Clinical features of retroviral syndrome in La Plata, Arge
ed cell death in primary infection/Expression of molecules r
pneumonia (PCP) and respiratory failure (ARF)/Validation
pneumonia (PCP) and respiratory failure (ARF)/Potential r
ved cellular immunity in HIV-1 infection following antiretrovir
suppressed rats during PCP/Extrapulmonary dissemination
V+ patients/Etiology of renal failure in HIV+ patients/Etiolog
are not associated with pelvic inflammatory disease in HIV-i
mbivirTM in subjects with and chronic HIV-1 infection/Adhere
asibility for diagnosis of primary HIV infection and estimation
nges in viral load during respiratory infections in HIV infectio
xide synthesis during SIVmac251 infection of Macaques/
ces HIV-1 replication in acutely infected primary Th2 cells and cell
-suppressing activity in infected-reservoir cells/Human rlL
CD4+ cells naturally or infected by HIV/CD28 costimulati
eatment with foscarnet/ Acyclovir-resistant herpes zoster in 18 HI
I therapy (HAART) and acyclovir therapy/Regression or stabilizat
ly developed polymeric adamantane analogue/Inhibition of HIV-1
ual behavior of persons addicted to narcotics/Sexual behavior of p
and syphilis among the prisoners/The simultanity of HIV
groups of HIV +ve drug patients/Evaluation of effectiven
program/Reduction of addictive and risk taking behaviour during
me strategy among drug addicts in Yugoslavia/Developing prevent
drug users/Recovering 'role in AIDS prevention for incarc
tics of HIV positive drug in FR Yugoslavia/Characteristics
erized medical record ( ADDIS ~)/Improving patients' enrollment i
ameters by HIV stage in Addis Abeba, Ethiopia/Clinical/Viro/Immu
ther anti-HIV agents/ Adefovir (PMEA) and PMPA show synergi
HIV infection/Safety of adefovir dipivoxil in the treatment of HIV in
ed open label study of dipivoxil (PreveonT, ADV) in com
ncreased sensitivity to and PMPA as well as decreased r
elop during PreveonTM ( dipivoxil) therapy do not decrease
herapy with PreveonTM ( dipivoxil) added to existing regim
sponses in Macaques/ Adenovirus-SIV env priming and boosting
Incrementazione della Adesione Necessaria alle Cure Erogate in

12198
12202
21161
22188
22436
115*/31177
31220
32127
32135
32328
42105
42161
60686
21153
21185
60407
32269
32209
41205
23242
60835
60868
43302
23251
43401
60884
42207
12135
41195
12386
22371
41214
41218
60706
11241
32386
12298

viral therapy (HEART)/
at the JCRC in Uganda/
ncy HIV Study (WIHS)/
ng HIV positive women/
larithromycin regimen/
Itisite interview project/
hronic HIV-1 infection/
owledge as predictors/
ncy HIV Study (WIHS)/
V+ women and nurses/
nd protease inhibitors/
stions to improve them/
ng HIV-positive women/
with guidelines for care/
nd a clinical trials unit/
atients of the inner city/
n HIV-infected patients/
Ministry of Health policy/
y - Porto Alegre, Brazil/
ments in a day-nursery/
es in the United States/
attenuating measures/
ur country comparison/
vs. clinical care setting/: Qualitative approach/
itors/Factors related to
vey (HTSS) to improve
wards childbearing and
) Course on medication
ease/Measurement of
herapy: Key factors for
te d'lvoire/Study drug
ychological factors and
t-team model/Ensuring
s/Counselling PWAs on
/Strategies to optimise
-based HIV medication
e on antiretroviral (AR)
nwide protease inhibitor
n/Antretroviral use and
s and age are related to
HIV (PLWH) to improve
asing active drug users'
ed adults/Self-reported

Adherence to proteinase inhibitor based hi

and compliance in tuberculosi 448*/22129
with colposcopy among wome 22320
to gynecologic examinations a 32132
patterns in patients with sympt 32324
to currently prescribed antiretr 392*/32326
to quadruple therapy with aba 32328
to protease inhibitor (PI) thera 32337
to antiretroviral therapy (ART) 32347
barriers to complex antiretrovir 65*/32352
re-framed in the big picture: A 32365
to highly active antiretroviral tr 32367
to antiretroviral therapy amon 32374
to antiretroviral medications in 32378
and antiretroviral responses to 32380
to highly active antiretroviral th 32389
to antiretroviral therapy in HIV- 32392
to antiretroviral therapy: The F 32396
to ACTG 076 regimen in a dev 32401
to treatments in a day-nursery 34325
to opportunistic infections (Ols 42212
of patients with AIDS to treatm 42442
to anti-retroviral therapy: A fou 60129
to HAART in clinical trials vs. cl 60356
evaluation of antiretroviral (AR 60843
adherence (ADH) with protease inhibitors 12400
and quality of out-patient care/ 12445
to safer sex rules in a cohort of 14111
- A pilot study/Impact of THE ( 14271
to clinical guidelines and patie 22379
period/Nursing interventions f 22471
and tolerance within a randomi 31*/23280
to combination therapies: A pil 24282: A patient-team model/Ensuri 24286
issues/Counselling PWAs on 24330
to highly active antiretroviral tr 388*/32322
referral clinic/Interventions an 390*/32323
among HIV-infected out-patien 32325
program/Nationwide protease 32327
in a cohort of 696 HIV+ pregna 32329
to combination therapy in HIV- 32331
to highly active antiretroviral th 32333
to HIV therapeutics/Increasing 393*/32336
to combination antiretroviral m 32338

on and more protected acts with a choice of methods: The women
n HIV infected inmates/ Acupuncture /an alternative to acting out o
evated transaminases/ treatment in people with HC
icacy of a standardized acupuncture regimen for neuropathic pai
I): A cohort description/ Acute primary HIV infection (APHI): A coh
a in a patient with AIDS/ disseminated histoplasmosis and P
agnosed HIV+ women/ stress disorder assessment and inte
n HIV-infected women/ pelvic inflammatory disease associ
mmunodeficiency virus acute infection and CCR5, CCR1, IFNy, R
cell dysfunctions during infection of SIVmac251 infected Ma
nd non-pathogenic SIV infections/t-Chemokine responses
+ T-cell differentiation in viral and chronic HIV-1 infection: Per
ve T cell subsets during infection (Al) with HIV and response